Moderna and Merck Announce Positive Results for mRNA Melanoma Vaccine in Late-Stage Trial

Moderna and Merck have reported successful outcomes from their late-stage clinical trial for an mRNA-based cancer vaccine targeting melanoma. This significant development could offer a new therapeutic approach for melanoma patients, potentially marking a major advancement in the field of oncology and vaccine technology.